• INSTRUCTIONS

MERCHANT & GOLULD United States Patent Ar COMBINED DECLARATION AND POWER OF ATTORNEY

	I verily believe I am to inventors are named below)	ne original, first and sole inventor (of the subject matter which is clair	if only one name is listed below ned and for which a patent is so	 or a joint inventor (if pluinght on the invention entitle
Insert TITLE of invention	The Use of Pr	oteasome Inhibit	ors for Treatin	g Cancer,
	Inflammation,	<u>Autoimmune Dise</u>		ction and tic Shock
Check a or b	The specification of which			
	a. []] is attached hereto			
	b. 🛭 was filed onJ1	me 29, 1999		
If "b" checked, complete	as application serial no			
	and was amended on			(if applicable)
If PCT Application	(in the case of PCT-filed ap	plication)		
Insert Int. application	described and claimed in in	ternational no. PCT/CA98	/01010 filed 29	October 1998
nsert lat. application number & filing date	and as amended on N	(if any), which I	have reviewed and for which I so	olicit a United States patent
: : :	I hereby state that I have re amended by any amendmen	viewed and understand the content at referred to above.	s of the above identified specific	ation, including the claims
том, том, том, том, том, том, том, том,	I acknowledge the duty to Title 37, Code of Federal R	disclose information which is mate egulations,§ 1.56(a). (Reprinted on	rial to the examination of this a back side).	pplication in accordance w
Trust Trust	of inventor's certificate list	rity benefits under Title 35, United bed below and have also identified bethat of the application on the basis of	elow any for c ign application for	eign application(s) for pate patent or inventor's certific
Prior applications Check a or b	a. 🗆 no such applications l	navebeen filed.		
	b 🖄 such applications hav	e been filed as follows:		
	FOREIG	N APPLICATION(S), IF ANY, CLA		
	COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
	CA	2,219,867	31 Octobre 1997	
if "b" checked, complete				
	ALL FOREIG	N APPLICATION(S), IF ANY, FILE		
	COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code\$ 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation\$ 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

For Continuation-in-Part	
(CIP) Applications, complete	

Revised 1/25/99

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)
·		



- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by \$.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
 - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with he filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim;
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
 - (1) Each inventor named in the application:
 - (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

Revised 1/25/99

Albrecht, John W.	Reg. No. 40.481	Gorman Also G	Pag No 19 477	B. L. D. 1114	
Anderson, Gregg I.	Reg. No. 38,828	Gould, John D.	Reg. No. 18,472	Pauly, Duniel M.	Reg. No. 40,123
Ansems, Gregory M.	Reg. No. 42 264		Reg. No. 18 223-	Plunkett, Theodore	Reg. No. 37 209
	·	Gregson, Richard	Reg. No. 41.804	Pytel, Melissa J.	Reg. No. 37,209
Batzli, Brian H.	Reg. No. 12,960,	Gresens, John J.	Reg. No. 33,112	Reich, John C.	Reg. No. 37,703
Beard, John L.	Reg. No. 27,612	Hamre, Curtis B.	Reg. No. 29,165	Reiland, Earl D.	Reg. No. 25,767
Berman, Charles	Reg. No. 29,249	Hillson, Randall A.	Reg. No. 11,838	Rittmaster, Ted R.	Reg. No. 32,933
Black, Bruce	Reg. No. 41,622	Johnston, Scott W.	Reg. No. 39,721	Schmaltz, David G.	Res. No. 39,828
Blasdell, Thomas L.	Reg. No. 31, 329	Kastelic, Joseph M.	Reg. No. 37,160	Schuman, Mark D.	Reg. No. 31, 197
Bogucki, Raymond A.	Reg. No. 17.426	Kettelberger, Denise	Reg. No. 33,924	Schumann, Michael D.	Reg. No. 30,422
Bruess, Steven C.	Reg. No. 34,130	Knearl, Homer L.	Reg. No. 21,197	Sebald, Gregory A.	Reg. No. 33,280
Byrne, Linda M.	Reg. No. 32,404	Komanduri, Janaki	Reg. No. 40,684	Skooe, Mark T.	Reg. No. 40,178
Carlson, Alan G.	Reg. No. 25,959	Kowalchyk, Alan W.	Reg. No. 11.535	Soderberg, Richard	Reg. No. P-43,352
Carter, Charles G.	Reg. No. 35,093	Kowalchyk, Katherine M.		Sumper, John P.	Reg. No. 29 114
Caspers, Philip P.	Reg. No. 33,227	Kubota, Glenn M.	Reg. No. P-44 197	Sumpers, John S.	Reg. No. 24,216
Chiapetta, James R.	Reg. No. 39,634	Lacy, Paul A.	Reg. No. 38 946	Tellekson, David K.	Reg. No. 32 314
Clifford, John A.	Reg. No. 30,247	Larson, James A.	Reg. No. 40,443	Trembath, Jon R.	Reg. No. 38,344
Cochran, William W.	Reg. No. 26,652	Lasky, Michael B.	Reg. No. 29 555	Underhill, Albert L.	Reg. No. 27,403
Daignault, Ronald A.	Reg. No. 25,968	Liepa, Mara E.	Reg. No. 40.066		
Daley, Dennis R.	Reg. No. 34,994	Lindquist, Timothy A.	Reg. No. 40.201	Vandenburgh, J. Derek	Reg. No. 32,179
Dalglish, Leslie E.	Reg. No. 40,579	Lynch, David W.		Vrandenburgh, Anna M.	Reg. No. 39,868
Daulton, Julie R.		•	Reg. No. 36,204	Welter, Paul A.	Reg. No. 20,890
	Reg. No. 36,414	Marschang, Diane L.	Reg. No. 35,600	Whipps, Brian	Reg. No. P-43,261
DeVries Smith, Kate	Reg. No. 42,157	McDaniel, Karen D.	Reg. No. 37,674.	Wickhem, J. Scot	Reg. No. 41,376_
DiPietro, Mark J.	Reg. No. 28,707	McDonald, Daniel W.	Reg. No. 32,044	Williams, Douglas J.	Reg. No. 27.054
Edell, Robert T.	Reg. No. 20.187	McIntyre, Iain A.	Reg. No. 40,377	Witt, Jonelle	Reg. No. 41 980
Epp Ryan, Sandra	Reg. No. 39,667	McKenzie, Denise L.	Reg. No. P-43,790-	- Wood, Gregory B.	Reg. No. 28,133
Farber, Michael B.	Reg. No. 32,612	Mueller, Douglas P.	Reg. No_30,300-	Wood, William	Reg. P-42,236
Funk, Steven R.	Reg. No_37,830_	Nasiedlak, Tyler L.	Reg. No. 40,099-		Reg. No. 39,536
Glance, Robert J.	Reg. No. 40,620_	Nelson, Albin J.	Reg. No. 28,650-	-	
Golla, Charles E.	Reg. No. 26,896	Parker, Sandra M.	Reg. No. 36,233		

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant & Gould to the contrary.

Please direct all correspondence in this case to Merchant, Gould, Smith, Edell, Welter & Schmidt at the address indicated below (or if no address is specified, the first address):

- 3100 Norwest Center, 90 South Seventh Street; Minneapolis, MN 55402-4131 (Telephone No. (612) 332-5300)
- Independence Plaza, Suite 1400; 1050 17th St.; Denver, CO 80265-0100 (Telephone No. (303) 357-1670)
- Westwood Gateway II, Suite 400; 11150 Santa Monica Boulevard; Los Angeles, CA 90025-3395 (Telephone No. (310) 445-1140)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

			· ·	
1 2	FULL NAME OF	FAMILY NAME	FURST GIVEN NAME	SECOND GIVEN NAME
*	INVENTOR	WU	Jiangping	
١.	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
O	CTTZENSHIP	Brossard CA	Quebec, Canad	a Canada
۱.	POST OFFICE	POST OFFICE ADDRESS	сту	STATE & ZIP CODE/COUNTRY
Ľ	ADDRESS	8055 Rhone	Brossard, Queb	ed Canada J4X 2K9
0	FULL NAME OF	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	INVENTOR	WANG	Xin	
	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	CITIZENSHIP	Montréal_Cff	Quebec, Canada	
١.,	POST OFFICE	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
2	ADDRESS	3717 Dupuis #1	Montréal, Québe	ed Canada H3T 1E5
2	FULL NAME OF	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
-	INVENTOR			I
0	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
١٠	CTTIZENSHIP	·		j ,
3	POST OFFICE	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
اد	ADDRESS		. 1	
SIGNATURE OF INVENTOR 201 SIGNATURE OF INVENTOR 207 SIGNATURE OF INVENTOR				
DAT	- /	/ // DAIE	1	ATE
	July 15	1000 7	15 1000	

Insert FULL name(s)
AND address(es) of actual inventor(s)

 $Z.\omega$

Each inventor must sign & date

Note: No legalization or other witness required

Revised 1/25/99

For Additional Inventors:

Check box and attach sheet with same information, including date and signature.

VERIFIED STATEMENT CLARATION) CLAIMING SMAL NTITY STATUS (37 CFR 1.9(f) A...) 1.27 (d)) - NONPROFIT ORGANIZATION

Docket No. 9555.94-US-WO

Seri	al No.	Filing Date 29-JUN-1999	Patent No.	Issue Date				
Applicant/ WU, Jiangping and WANG, Xin Patentee:								
Invention: The Use of Proteasome Inhibitors for Treating Cancer, Inflammation, Autoimmune Disease,								
Graft Rejection and Septic Shock								
I hereby dec	clare that I am ar	n official empowered to act on l	behalf of the nonprofit organizat	ion identified below:				
NAME OF C	RGANIZATION							
ADDRESS (OF ORGANIZAT		d-Montpetit					
,		Montréal, Québec CANADA						
		H3C 3J7						
TYPE OF N	ONPROFIT OR	GANIZATION:						
<u>*</u> ≟ ⊠	University or of	ther Institute of Higher Education	on					
	ONPROFIT OR University or of Tax Exempt ur Nonprofit Scier	der Internal Revenue Service	Code (26 U.S.C. 501(a) and 50	1(c)(3))				
	Nonprofit Scier	ntific or Educational under State	ute of State of The United State	s of America				
-	Name of Sta	ate:	Citation of Statute:					
o Ti	· · · · · · · · · · · · · · · · · · ·	as Tax Exempt under Internal I Located in The United States	Revenue Service Code (26 U.S of America	.C. 501(a) and				
	-	as Nonprofit Scientific or Educa ocated in The United States of	ational under Statute of State of America	The United States of				
	Name of Sta	ate:	Citation of Statute:					
I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:								
	the specificatio	n to be filed herewith.						
\boxtimes	the application	identified above.						
	the patent iden	tified above.						
with regard	to the above ide	ntified invention.	een conveyed to and remain wi					

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

	obligation und	der contract such person	or law to as	sign, grant, con	nave assigned, granted, co vey, or license any rights in xists. is listed below.		
	FULL NAME ADDRESS			····	ier de l'Université de Montré n, Montréal, Québec, CANA	· · · · · · · · · · · · · · · · · · ·	
			Individual		Small Business Concern	X	Nonprofit Organization
	FULL NAME ADDRESS						
			Individual		Small Business Concern		Nonprofit Organization
	FULL NAME ADDRESS			**************************************			
Paris 118	FULL NAME		Individual		Small Business Concern		Nonprofit Organization
,)	ADDRESS						
I			Individual		Small Business Concern		Nonprofit Organization
The state of the s	Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27) I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)) I hereby declare that all statements made herein of my own knowledge are true and that all statements made or information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 or Title 18 of the United States Code, and that such willful false statement is directed.						status resulting in loss of of the issue fee or any (37 CFR 1.28(b)) all statements made on with the knowledge that th, under Section 1001 of
	NAME OF PE			Jean Yvon Tir			
	TITLE IN ORC				e of Industrial Liaison d Édouard-Montnetit, Mont	réal. Québec	CANADA H3C 3.17
	ADDRESS OF PERSON SIGNING: 2900 Boulevard Édouard-Montpetit, Montréal, Québec, CANADA H3C 3J7 SIGNATURE: July 15, 1999						

VERIFIED STATEMENT (CLARATION) CLAIMING SMALL STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION

Docket No. 9555.94-US-WO

<u> </u>								
Serial No.	Filing Date 29-JUN-1999	Patent No.	Issue Date					
Applicant/ WU, Jiangping and WANG, Xin Patentee:								
Invention: The Use of Proteasome Inhibitors for Treating Cancer, Inflammation, Autoimmune Disease, Graft								
Rejection an dSeptic Sho	ock							
-								
I hereby declare that I a	am an official empowered to act on	behalf of the nonprofit organizat	tion identified below:					
NAME OF ORGANIZA		Centre Hospitalier the l'Univers	ité de Mon tréal					
_ ADDRESS OF ORGAN	NIZATION: <u>Campus Hôtel-Dieu</u> 3850, rue St-Urbain							
	Montréal, Québec							
	CANADA H2W 1T8							
TYPE OF NONPROFIT	Γ ORGANIZATION:							
☐ University☐ Tax Exem	or other Institute of Higher Educat	titute of Higher Education						
☐ ☐ Tax Exem	npt under Internal Revenue Service	Code (26 U.S.C. 501(a) and 50	1(c)(3))					
☐ ☐ Nonprofit Name	Scientific or Educational under Sta of State:	tute of State of The United State Citation of Statute:	s of America					
-	ualify as Tax Exempt under Internal (3)) if Located in The United States	· ·	.C. 501(a) and					
⊠ vvouid Qu Americ	ualify as Nonprofit Scientific or Educ ca if Located in The United States of of State:							
_	he above-identified nonprofit organ rposes of paying reduced fees to t	•	•					
☐ the specifi	ication to be filed herewith.							
★ the application	ation identified above.							
☐ the patent	t identified above.							
I hereby declare that ri with regard to the abov	ights under contract or law have by identified invention.	een conveyed to and remain wi	th the nonprofit organization					
If the rights held by	the above-identified nonprofit or	ganization are not exclusive, e	each individual, concern or					

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

				nave assigned, granted, ovey, or license any rights i		
	•		r organization ex		•	
⊠ eac	h such perso	on, concern	or organization	is listed below.		
	**					
FULL NAME ADDRESS	Université d	-	d-Montnetit M	ontréal, Québec, CANADA	H3C 3 17	
ADDITEOU		Individual		Small Business Concern	<u> </u>	Nonprofit Organization
FULL NAME						3
ADDRESS						
		Individual		Small Business Concern		Nonprofit Organization
FULL NAME						
ADDRESS				· · · · · · · · · · · · · · · · · · ·		
		Individual		Small Business Concern		Nonprofit Organization
FULL NAME						
ADDRESS						
		Individual		Small Business Concern		Nonprofit Organization
≟ Separate ve	rified statem	nents are re	equired from ea	ach named person conce	ern or organiza	ation having rights to the
			small entities. (3	•	on organiza	and the time of the time
entitlement i	to small ent	ity status p	orior to paying,		g, the earliest	status resulting in loss of of the issue fee or any . (37 CFR 1.28(b))
information a willful false s Title 18 of th	and belief are statements a e United Sta	e believed t nd the like tes Code, a	to be true; and so made are pu and that such wi	further that these stateme unishable by fine or impris	ents were made conment, or bo jeopardize the	t all statements made on e with the knowledge that th, under Section 1001 of validity of the application,
	-					
NAME OF PE	RSON SIGN	IING:	Pavel HAMET	•		
TITLE IN ORC	SANIZATION	l:	Directeur de la	recherche		
ADDRESS OF	PERSON S	SIGNING:	3850, rue St-U	rbain, Montréal, Québec,	CANADA H2V	V 1T8
	\mathcal{U}					
SIGNATURE:	91	Mehn	Lu Lu	DAT	re: 15 4	hu/let 1999
		1	· · · · · · · · · · · · · · · · · · ·			Wy W / T
					V	